Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple drug tweak metabolism in obesity?

NCT ID NCT05028803

Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether sodium phenylbutyrate can lower levels of branched chain amino acids (BCAAs) in the blood of obese and prediabetic men. High BCAAs are linked to insulin resistance and type 2 diabetes. Researchers also looked at how the drug affects blood sugar, insulin sensitivity, and muscle protein building. The trial involved 8 men and was completed at the University of Nottingham.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sodium phenylbutyrate
What this could lead to
If successful, this could point toward a way to improve metabolic health in people with obesity or prediabetes by lowering certain amino acids.
What could go wrong
This is a very small, early-stage study with only 8 participants, so results may not apply to the general population. The drug may not meaningfully affect blood sugar or insulin sensitivity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

8 people

The number who actually took part.

Started

Sep 2021

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Participant is willing and able to give informed consent for participation in the study * Not currently taking any medications * Males between the ages of 18 - 60 * BMI ≥ 30 kg·m2 * FBG ≥ 6 mmol/L ≤ 7mmol/L or HbA1c ≥ 42 mmol/mol 48 ≤ mmol/mol Exclusion Criteria: * • Specify any diseases/disorders/ conditions that would preclude entry into the study * Females * History or current psychiatric illness * History or current neurological condition (e.g. epilepsy) * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance (this must remain for ALL UoN FMHS UREC approved studies) * A BMI \< 30kg·m2 * FBG \>7mmol/L/ or HbA1c \>48mmol/mol * Metabolic disease; Active inflammatory bowel disease * Chronic kidney disease * Malignancy * Recent (6 mo) steroid/ hormone therapy * Clotting dysfunction * Musculoskeletal/ neurological disorders * Active cardiovascular disease or recent cardiac event * Respiratory disease (not including well-controlled asthma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese non diabetic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obese non diabetic

Contacts and locations

Locations

  • University of Nottingham

    Derby, Derbyshire, DE22 3NE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.